PartnershipMay 11, 2026, 07:03 AM
Erasca Partners with Merck for AURORAS-1 Clinical Trial
AI Summary
Erasca, Inc. announced a clinical trial collaboration and supply agreement with Merck for the AURORAS-1 study. This study will evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Merck's anti-PD-1 therapy KEYTRUDA® for patients with RAS-mutant solid tumors. Erasca will sponsor the study, while Merck will supply pembrolizumab at no cost. The collaboration aims to improve therapeutic benefits and limit treatment resistance in RAS-driven cancers, which affect approximately 2.7 million patients annually worldwide.
Key Highlights
- Erasca partnered with Merck for the AURORAS-1 clinical trial.
- The study evaluates ERAS-0015 with KEYTRUDA® for RAS-mutant solid tumors.
- Merck is supplying pembrolizumab (KEYTRUDA®) at no cost for the trial.
- Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors.
- Early Phase 1 data for ERAS-0015 showed partial responses at doses as low as 8 mg QD.